ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

Johnson & Johnson is planning a phase 3 program for Rybrevant in colorectal cancer as a follow-up to its first indication in non-small cell lung cancer (NSCLC), after reporting encouraging results at ESMO.